Clinical Trials Logo

Filter by:
NCT ID: NCT05922202 Recruiting - Clinical trials for Role of Frailty in COPD

Influence of Frailty on Cardiovascular Events and Mortality in Patients With COPD.

FrCVCOPD
Start date: February 23, 2024
Phase:
Study type: Observational

Observational study on the influence of frailty on cardiovascular risk in COPD.

NCT ID: NCT05921877 Recruiting - Clinical trials for Amenorrhea Secondary

AMH and Functional Hypothalamic Amenorrhea

AMELIA
Start date: June 16, 2023
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to analyze AMH levels in patients with prolonged FHA (more than 2 years). Based on previous studies, we can assume that prolonged FHA may mimic a condition of primary hypogonadotropic hypogonadism, due to a lasting interruption of gonadotropin release. Furthermore, after the resumption of the spontaneous menstrual cycle, we will reanalyze AMH levels, which we hypothesize to find higher. If our hypotheses are confirmed correct, we could support the thesis that AMH is not a good index of ovarian reserve in patients with functional hypothalamic amenorrhea.

NCT ID: NCT05920356 Recruiting - Clinical trials for Non-Small Cell Lung Cancer (NSCLC)

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Start date: November 16, 2023
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to compare progression-free survival (PFS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.

NCT ID: NCT05919212 Recruiting - Clinical trials for Metastatic Breast Cancer

Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy

DIAMOND
Start date: February 1, 2023
Phase: N/A
Study type: Interventional

This is a prospective single-center pilot study phase II non randomized designed to explore the role of liquid biopsy in metastatic HER2-positive breast cancer patients treated with Trastuzumab deruxtecan (T-Dxd) as second line treatment according to international guidelines. All eligible patients to T-Dxd as second line treatment will receive T-Dxd intravenous at dose of 5,4 mg/kg every three weeks until progression disease or unacceptable toxicities. Subjects eligible to T-Dxd, who agree to participate in the study, will undergo serial blood samples for liquid biopsy (LB) until progression disease. The timing of blood drawing will be scheduled as follows: At each T-DXd administration for the first four cycles of T-Dxd (every three weeks). The next blood drawings will be done every three cycles of T-Dxd (every 9 weeks) until the thirteenth cycle. The next blood drawings will be done every six cycles of T-Dxd (every 18 weeks) until progression disease (documented by medical imaging) For all enrolled patients with available tumour tissue from primary diagnosis or last biopsy from recurrence, tissue samples will be requested for exploratory analysis.

NCT ID: NCT05918666 Recruiting - Clinical trials for Solid Tumours in Advanced Stages

National Register of Actionable Mutations

RATIONAL
Start date: October 27, 2018
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is the creation of a national network of precision medicine, which allows to increase, for Italian patients suffering from solid tumors, the possibility of access to more innovative therapies and to collect retrospectively their clinical data. For this purpose, a national register of actionable mutations in patients with solid tumors in advanced stage of disease will be created in which various individual, local and regional initiatives of genomic screening of cancer could merge.

NCT ID: NCT05918549 Recruiting - Clinical trials for Motion Analysis in Musculoskeletal Oncology

Movement Analysis in Musculoskeletal Oncology: a Pilot Study

AnMov
Start date: September 28, 2022
Phase:
Study type: Observational

Noninterventional, prospective, multicenter pilot study of patients with primary and secondary musculoskeletal tumors designed to investigate functional outcomes after therapy using both subjective and quantitative motion detection techniques

NCT ID: NCT05918536 Recruiting - Neoplasms Clinical Trials

Orthopedic Oncology Surgery: Navigation, Intraoperative Imaging and Virtual Reality

Start date: May 17, 2022
Phase:
Study type: Observational

Noninterventional, prospective study of patients operated on for musculoskeletal neoplasms designed to evaluate the quality of surgical margins achievable with the use of navigated Intraoperative CT

NCT ID: NCT05918510 Recruiting - Clinical trials for Lymph Node Metastasis

Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus

Start date: April 4, 2022
Phase:
Study type: Observational

Based on the evidence summarized in the introduction, the clinician hypothesize that the detection of the presence and expression of HPV-DNA, certain miRNAs, and a certain mutational profile in the tissues and biological fluids of these patients, may have important prognostic and diagnostic value not only in HPV-related OPSCCs but also in HPV+ occult T. Accordingly, this study aims to aim to better characterize their potential as biomarkers and to detect the possibility of their their use to implement the sensitivity and specificity of radiological methodologies (PET-CT and MRI), already in use in clinical practice, for monitoring disease progression in this specific subgroup. Finally, by using the collected material to generate organoids and Patient Derived Xenograft (PDX), the study also aims to identify possible new molecular drugs, which could solve the problem of resistance to radiochemotherapy.

NCT ID: NCT05918302 Recruiting - Clinical trials for Neuroendocrine Tumors

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

LEVEL
Start date: October 27, 2023
Phase: Phase 3
Study type: Interventional

LEVEL trial aims to demonstrate the higher efficacy of 177Lu-edotreotide over everolimus in patients with well to moderately differentiated neuroendocrine tumors of the lung and thymus who require systemic therapy. It is hypothesized that 177Lu-edotreotide may significantly increase the progression-free survival (PFS) compared to everolimus in lung and thymic carcinoids.

NCT ID: NCT05917795 Recruiting - Clinical trials for End Stage Renal Disease

Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates

ESGiTXKidney
Start date: September 24, 2023
Phase: N/A
Study type: Interventional

The aim of this pilot prospective interventional study is to evaluate the efficacy of endoscopic sleeve gastroplasty (ESG) in allowing obese subjects (≥35 kg/m2) with end stage renal disease who need of kidney transplantation to reduce their BMI below 35 in order to be inserted in the waiting list BMI. The main question[s] it aims to answer are: Is the procedure effective in reducing BMI to the target level in 12 months? Which is the effect on weight loss, quality of life and obesity-related comorbidities? Participants will undergo ESG as per standard clinical practice and followed up to 12 months before transplantation and for 12 months after transplantation.